NaturalShrimp Inc 8-K

What Happened
NaturalShrimp Incorporated announced on March 17, 2026 that it entered an Intellectual Property Acquisition and Management Transition Agreement with Hydrenesis, Inc. and David Antelo. Under the agreement the company will transition toward commercializing aquaculture and water‑treatment technologies, receive certain intellectual property and related technology assets from Hydrenesis, and transfer governance/control in accordance with the agreement. As part of the change in control, David Antelo was appointed Chief Executive Officer and the sole director immediately; the company expects to expand the board to three directors. Former executives Gerald Easterling (CEO), Bill Delgado (CFO) and Tom Untermyer (COO) resigned; the filing states these resignations were not due to any disagreement with the company.

Key Details

• Agreement date: March 17, 2026 (filed on Form 8‑K March 30, 2026).
• Debt conversion: approximately $1,034,112 owed to Hydrenesis will be converted into equity at closing.
• Capital structure changes: Certificates of Designation for Series P, Series P‑2 and Series L Preferred Stock have been approved and executed (to be filed with Nevada), and legacy securities (including Series A and Series F preferred) will be restructured, amended, cancelled or exchanged into Series L.
• Governance: the agreement grants control over board composition and executive authority to effect the change in control; Antelo is appointed CEO and sole director effective March 17, 2026.

Why It Matters
For investors, this filing signals a material change in control, leadership and strategic direction. The company is acquiring IP and shifting focus to aquaculture and water‑treatment commercialization, which could affect future revenue opportunities. The conversion of roughly $1.03 million of debt into equity and the restructuring of preferred stock may materially change the company’s capital structure and existing security holders’ rights (potential dilution and altered preferences). The appointment of a sole director/CEO centralizes decision-making; investors should monitor subsequent filings for details on the IP transfer, timing of closings, board composition, and any financial impacts or dilution disclosures.